{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:25:04Z","timestamp":1793744704558,"version":"4.6.1"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41571-024-00913-y","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T16:10:10Z","timestamp":1720023010000},"page":"590-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins"],"prefix":"10.1038","volume":"21","author":[{"given":"Paola","family":"Neri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4202-7127","authenticated-orcid":false,"given":"No\u00e9mie","family":"Leblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Gulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"913_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood 111, 2962\u20132972 (2008).","journal-title":"Blood"},{"key":"913_CR2","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","volume":"125","author":"P Moreau","year":"2015","unstructured":"Moreau, P., Attal, M. & Facon, T. Frontline therapy of multiple myeloma. Blood 125, 3076\u20133084 (2015).","journal-title":"Blood"},{"key":"913_CR3","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","volume":"125","author":"AK Nooka","year":"2015","unstructured":"Nooka, A. K., Kastritis, E., Dimopoulos, M. A. & Lonial, S. Treatment options for relapsed and refractory multiple myeloma. Blood 125, 3085\u20133099 (2015).","journal-title":"Blood"},{"key":"913_CR4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar, S. V. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am. J. Hematol. 97, 1086\u20131107 (2022).","journal-title":"Am. J. Hematol."},{"key":"913_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"913_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fonc.2020.00636","volume":"10","author":"N Leblay","year":"2020","unstructured":"Leblay, N., Maity, R., Hasan, F. & Neri, P. Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities. Front. Oncol. 10, 636 (2020).","journal-title":"Front. Oncol."},{"key":"913_CR7","doi-asserted-by":"publisher","first-page":"606368","DOI":"10.3389\/fonc.2020.606368","volume":"10","author":"L Yamamoto","year":"2020","unstructured":"Yamamoto, L., Amodio, N., Gulla, A. & Anderson, K. C. Harnessing the immune system against multiple myeloma: challenges and opportunities. Front. Oncol. 10, 606368 (2020).","journal-title":"Front. Oncol."},{"key":"913_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41591-023-02703-y","volume":"30","author":"S Trudel","year":"2024","unstructured":"Trudel, S. et al. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial. Nat. Med. 30, 543\u2013551 (2024).","journal-title":"Nat. Med."},{"key":"913_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/hematology.2023000434","volume":"2023","author":"RS Firestone","year":"2023","unstructured":"Firestone, R. S. & Mailankody, S. Current use of CAR T cells to treat multiple myeloma. Hematology 2023, 340\u2013347 (2023).","journal-title":"Hematology"},{"key":"913_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1182\/hematology.2023000433","volume":"2023","author":"H Lee","year":"2023","unstructured":"Lee, H., Neri, P. & Bahlis, N. J. Current use of bispecific antibodies to treat multiple myeloma. Hematol. Am. Soc. Hematol. Educ. Program. 2023, 332\u2013339 (2023).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"913_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau, C. H., Steeg, P. S. & Figg, W. D. Antibody-drug conjugates for cancer. Lancet 394, 793\u2013804 (2019).","journal-title":"Lancet"},{"key":"913_CR12","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"913_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"913_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls, A. M., Coupet, T. A. & Sentman, C. L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol. 93, 290\u2013296 (2015).","journal-title":"Immunol. Cell Biol."},{"key":"913_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","volume":"43","author":"S Offner","year":"2006","unstructured":"Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P. & Baeuerle, P. A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 43, 763\u2013771 (2006).","journal-title":"Mol. Immunol."},{"key":"913_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Riviere, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"913_CR17","doi-asserted-by":"publisher","first-page":"m3176","DOI":"10.1136\/bmj.m3176","volume":"370","author":"UA Shah","year":"2020","unstructured":"Shah, U. A. & Mailankody, S. Emerging immunotherapies in multiple myeloma. BMJ 370, m3176 (2020).","journal-title":"BMJ"},{"key":"913_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1172\/JCI18025","volume":"112","author":"DT Avery","year":"2003","unstructured":"Avery, D. T. et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112, 286\u2013297 (2003).","journal-title":"J. Clin. Invest."},{"key":"913_CR19","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai, Y. T. et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127, 3225\u20133236 (2016).","journal-title":"Blood"},{"key":"913_CR20","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","volume":"165","author":"A Hatzoglou","year":"2000","unstructured":"Hatzoglou, A. et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-\u03baB, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J. Immunol. 165, 1322\u20131330 (2000).","journal-title":"J. Immunol."},{"key":"913_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/cbf.3169","volume":"34","author":"X Shen","year":"2016","unstructured":"Shen, X. et al. Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways. Cell Biochem. Funct. 34, 104\u2013110 (2016).","journal-title":"Cell Biochem. Funct."},{"key":"913_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent, S. A. et al. \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun. 6, 7333 (2015).","journal-title":"Nat. Commun."},{"key":"913_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727\u2013738 (2012).","journal-title":"Br. J. Haematol."},{"key":"913_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1182\/blood-2023-173550","volume":"142","author":"D Vishwamitra","year":"2023","unstructured":"Vishwamitra, D. et al. Longitudinal correlative profiles of responders, nonresponders, and those with relapse on treatment with teclistamab in the phase 1\/2 MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma. Blood 142, 455\u2013455 (2023).","journal-title":"Blood"},{"key":"913_CR25","doi-asserted-by":"publisher","unstructured":"Cortes-Selva, D. et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in MajesTEC-1. Blood https:\/\/doi.org\/10.1182\/blood.2023022823 (2024).","DOI":"10.1182\/blood.2023022823"},{"key":"913_CR26","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai, Y. T. et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123, 3128\u20133138 (2014).","journal-title":"Blood"},{"key":"913_CR27","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"R Montes de Oca","year":"2021","unstructured":"Montes de Oca, R. et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol. Cancer Ther. 20, 1941\u20131955 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"913_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"issue":"Suppl. 2","key":"913_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01.HS9.0000936252.25785.17","volume":"7","author":"A Nooka","year":"2023","unstructured":"Nooka, A. et al. Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: final analysis of the DREAMM-2 trial [abstract P31]. Hemasphere 7 (Suppl. 2), 27\u201328 (2023).","journal-title":"Hemasphere"},{"key":"913_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4155\/tde-2016-0002","volume":"7","author":"M Vankemmelbeke","year":"2016","unstructured":"Vankemmelbeke, M. & Durrant, L. Third-generation antibody drug conjugates for cancer therapy \u2013 a balancing act. Ther. Deliv. 7, 141\u2013144 (2016).","journal-title":"Ther. Deliv."},{"key":"913_CR31","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 10, e801\u2013e812 (2023).","journal-title":"Lancet Haematol."},{"key":"913_CR32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos, M. A. et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2403407 (2024).","journal-title":"N. Engl. J. Med."},{"key":"913_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa240509","author":"V Hungria","year":"2024","unstructured":"Hungria, V. et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa240509 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 16","key":"913_CR34","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1200\/JCO.2023.41.16_suppl.8025","volume":"41","author":"C Li","year":"2023","unstructured":"Li, C. et al. CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed\/refractory multiple myeloma: updated results of phase 1b\/2 study (FUMANBA-1) [abstract]. J. Clin. Oncol. 41 (Suppl. 16), 8025 (2023).","journal-title":"J. Clin. Oncol."},{"key":"913_CR35","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40291-023-00673-y","volume":"27","author":"SJ Keam","year":"2023","unstructured":"Keam, S. J. Equecabtagene autoleucel: first approval. Mol. Diagn. Ther. 27, 781\u2013787 (2023).","journal-title":"Mol. Diagn. Ther."},{"issue":"Suppl. 1","key":"913_CR36","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1182\/blood-2023-184373","volume":"142","author":"C Fu","year":"2023","unstructured":"Fu, C. et al. Three-year follow-up on efficacy and safety results from phase 1 lummicar study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma [abstract]. Blood 142 (Suppl. 1), 4845 (2023).","journal-title":"Blood"},{"key":"913_CR37","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"913_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"15 Suppl.","key":"913_CR39","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","volume":"39","author":"JLD Anderson","year":"2021","unstructured":"Anderson, J. L. D. et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results [abstract]. J. Clin. Oncol. 39 (Suppl. 15), 8016 (2021).","journal-title":"J. Clin. Oncol."},{"key":"913_CR40","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1182\/blood-2022-164884","volume":"140","author":"CJ Ferreri","year":"2022","unstructured":"Ferreri, C. J. et al. Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed\/refractory multiple myeloma (RRMM) who have received a prior BCMA-targeted therapy: real world, multi-institutional experience. Blood 140, 1856\u20131858 (2022).","journal-title":"Blood"},{"key":"913_CR41","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"913_CR42","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"16 Suppl.","key":"913_CR43","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma [abstract]. J. Clin. Oncol. 41 (Suppl. 16), 8009 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"913_CR44","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2023-178882","volume":"142","author":"J Hillengass","year":"2023","unstructured":"Hillengass, J. et al. The phase 2 CARTITUDE-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B) [abstract]. Blood 142 (Suppl. 1), 1021 (2023).","journal-title":"Blood"},{"key":"913_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"913_CR46","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia, P. et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 142, 1243\u20131248 (2023).","journal-title":"Blood"},{"key":"913_CR47","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen, O. et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat. Med. 27, 2099\u20132103 (2021).","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"913_CR48","doi-asserted-by":"publisher","first-page":"7433","DOI":"10.1182\/blood-2022-159156","volume":"140","author":"L Mikkilineni","year":"2022","unstructured":"Mikkilineni, L. et al. T cells expressing a fully-human anti-BCMA chimeric antigen receptor with a heavy-chain-only antigen-recognition domain exhibit rapid and durable activity against multiple myeloma [abstract]. Blood 140 (Suppl. 1), 7433\u20137434 (2022).","journal-title":"Blood"},{"key":"913_CR49","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","volume":"7","author":"MJ Frigault","year":"2023","unstructured":"Frigault, M. J. et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 7, 768\u2013777 (2023).","journal-title":"Blood Adv."},{"issue":"Suppl. 1","key":"913_CR50","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/blood-2022-160038","volume":"140","author":"LJ Costa","year":"2022","unstructured":"Costa, L. J. et al. Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) Nex T chimeric antigen receptor (CAR) T cell therapy CC-98633\/BMS-986354 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) [abstract]. Blood 140 (Suppl. 1), 1360\u20131362 (2022).","journal-title":"Blood"},{"key":"913_CR51","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat. Med. 29, 422\u2013429 (2023).","journal-title":"Nat. Med."},{"key":"913_CR52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei, H. et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J. Hematol. Oncol. 14, 161 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"913_CR53","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan, Z. et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 6, e521\u2013e529 (2019).","journal-title":"Lancet Haematol."},{"key":"913_CR54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"16 Suppl.","key":"913_CR55","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","volume":"41","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk, N. W. C. J. et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM) [abstract]. J. Clin. Oncol. 41 (Suppl. 16), 8011 (2023).","journal-title":"J. Clin. Oncol."},{"key":"913_CR56","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis, N. J. et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat. Med. 29, 2570\u20132576 (2023).","journal-title":"Nat. Med."},{"key":"913_CR57","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin, A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. 29, 2259\u20132267 (2023).","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"913_CR58","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1182\/blood-2023-182130","volume":"142","author":"M Tomasson","year":"2023","unstructured":"Tomasson, M. et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM) [abstract]. Blood 142 (Suppl. 1), 3385 (2023).","journal-title":"Blood"},{"key":"913_CR59","doi-asserted-by":"publisher","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","volume":"15","author":"K Ball","year":"2023","unstructured":"Ball, K., Dovedi, S. J., Vajjah, P. & Phipps, A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs 15, 2181016 (2023).","journal-title":"MAbs"},{"key":"913_CR60","doi-asserted-by":"publisher","unstructured":"Verkleij, C. P. M. et al. T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3333 (2024).","DOI":"10.1158\/1078-0432.CCR-23-3333"},{"key":"913_CR61","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","volume":"7","author":"F Mazahreh","year":"2023","unstructured":"Mazahreh, F. et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 7, 3069\u20133074 (2023).","journal-title":"Blood Adv."},{"key":"913_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje, N. et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 13, 116 (2023).","journal-title":"Blood Cancer J."},{"key":"913_CR63","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1182\/blood-2023-177968","volume":"142","author":"S Jagannath","year":"2023","unstructured":"Jagannath, S. et al. Patterns of response to 200 mg linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up of the linker-MM1 study. Blood 142, 4746\u20134746 (2023).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"913_CR64","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1182\/blood-2023-180013","volume":"142","author":"N Bar","year":"2023","unstructured":"Bar, N. et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen (BCMA) \u00d7 CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study [abstract]. Blood 142 (Suppl. 1), 2011 (2023).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"913_CR65","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/blood-2023-182388","volume":"142","author":"R Vij","year":"2023","unstructured":"Vij, R. et al. Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma [abstract]. Blood 142 (Suppl. 1), 3378 (2023).","journal-title":"Blood"},{"key":"913_CR66","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd.2017.178","volume":"16","author":"AS Hauser","year":"2017","unstructured":"Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schioth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug. Discov. 16, 829\u2013842 (2017).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"913_CR67","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11, eaau7746 (2019).","journal-title":"Sci. Transl. Med."},{"key":"913_CR68","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","volume":"122","author":"S Inoue","year":"2004","unstructured":"Inoue, S., Nambu, T. & Shimomura, T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J. Invest. Dermatol. 122, 565\u2013573 (2004).","journal-title":"J. Invest. Dermatol."},{"key":"913_CR69","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti, K. et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 135, 1232\u20131243 (2020).","journal-title":"Blood"},{"key":"913_CR70","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0167-4781(01)00197-X","volume":"1518","author":"H Brauner-Osborne","year":"2001","unstructured":"Brauner-Osborne, H. et al. Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochim. Biophys. Acta 1518, 237\u2013248 (2001).","journal-title":"Biochim. Biophys. Acta"},{"key":"913_CR71","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont, M. J. et al. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 134, 1585\u20131597 (2019).","journal-title":"Blood"},{"key":"913_CR72","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody, S. et al. GPRC5D-targeted 1CAR T cells for myeloma. N. Engl. J. Med. 387, 1196\u20131206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"913_CR73","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1200\/JCO.2024.42.16_suppl.7511","volume":"42","author":"H Huang","year":"2024","unstructured":"Huang, H. et al. OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed\/refractory multiple myeloma: long term follow-up results of phase 1 study (POLARIS). J. Clin. Oncol. 42, 7511 (2024).","journal-title":"J. Clin. Oncol."},{"key":"913_CR74","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2023-181857","volume":"142","author":"S Bal","year":"2023","unstructured":"Bal, S. et al. BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study. Blood 142, 219\u2013219 (2023).","journal-title":"Blood"},{"key":"913_CR75","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/JCO.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia, J. et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J. Clin. Oncol. 41, 2583\u20132593 (2023).","journal-title":"J. Clin. Oncol."},{"key":"913_CR76","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fern\u00e1ndez de Larrea","year":"2020","unstructured":"Fern\u00e1ndez de Larrea, C. et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 1, 146\u2013154 (2020).","journal-title":"Blood Cancer Discov."},{"key":"913_CR77","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/blood-2023-181613","volume":"142","author":"J Fu","year":"2023","unstructured":"Fu, J. et al. Efficacy of human iPSC-derived CAR-NK cells targeting multiple myeloma cells. Blood 142, 4802 (2023).","journal-title":"Blood"},{"key":"913_CR78","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1182\/blood-2022-159289","volume":"140","author":"Z Cao","year":"2022","unstructured":"Cao, Z. et al. Allogeneic CAR-NK cell therapy targeting both BCMA and GPRC5D for the treatment of multiple myeloma. Blood 140, 7378\u20137378 (2022).","journal-title":"Blood"},{"key":"913_CR79","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1182\/blood-2022-170501","volume":"140","author":"J Reiser","year":"2022","unstructured":"Reiser, J. et al. FT555: off-the-shelf CAR-NK cell therapy co-targeting GPRC5D and CD38 for the treatment of multiple myeloma. Blood 140, 4560\u20134561 (2022).","journal-title":"Blood"},{"key":"913_CR80","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1158\/1538-7445.AM2022-6020","volume":"82","author":"W Huang","year":"2022","unstructured":"Huang, W. et al. Abstract 6020: preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma. Cancer Res. 82, 6020\u20136020 (2022).","journal-title":"Cancer Res."},{"key":"913_CR81","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232\u20132244 (2022).","journal-title":"N. Engl. J. Med."},{"key":"913_CR82","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2023-182330","volume":"142","author":"L Sanchez","year":"2023","unstructured":"Sanchez, L. et al. Clinical outcomes of subsequent therapies in patients with relapsed\/refractory multiple myeloma following talquetamab treatment: analyses from the phase 1\/2 monumenTAL-1 study. Blood 142, 2007\u20132007 (2023).","journal-title":"Blood"},{"key":"913_CR83","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"C Schinke","year":"2023","unstructured":"Schinke, C. et al. Pivotal phase 2 monumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J. Clin. Oncol. 41, 8036\u20138036 (2023).","journal-title":"J. Clin. Oncol."},{"key":"913_CR84","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1182\/blood-2023-187242","volume":"142","author":"AJ Jakubowiak","year":"2023","unstructured":"Jakubowiak, A. J. et al. Updated results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study. Blood 142, 3377\u20133377 (2023).","journal-title":"Blood"},{"key":"913_CR85","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2022-157988","volume":"140","author":"C Carlo-Stella","year":"2022","unstructured":"Carlo-Stella, C. et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood 140, 397\u2013399 (2022).\u00a0","journal-title":"Blood"},{"key":"913_CR86","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S2152-2650(23)01572-0","volume":"23","author":"S Harrison","year":"2023","unstructured":"Harrison, S. et al. OA-05 Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses. Clin. Lymphoma Myeloma Leuk. 23, S3\u2013S4 (2023).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"913_CR87","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","volume":"11","author":"K Elkins","year":"2012","unstructured":"Elkins, K. et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol. Cancer Thera 11, 2222\u20132232 (2012).","journal-title":"Mol. Cancer Thera"},{"key":"913_CR88","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","volume":"18","author":"AG Polson","year":"2006","unstructured":"Polson, A. G. et al. Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int. Immunol. 18, 1363\u20131373 (2006).","journal-title":"Int. Immunol."},{"key":"913_CR89","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/sj.leu.2404445","volume":"21","author":"T Ise","year":"2007","unstructured":"Ise, T. et al. Elevation of soluble CD307 (IRTA2\/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 21, 169\u2013174 (2007).","journal-title":"Leukemia"},{"key":"913_CR90","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1074-7613(01)00109-1","volume":"14","author":"G Hatzivassiliou","year":"2001","unstructured":"Hatzivassiliou, G. et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 14, 277\u2013289 (2001).","journal-title":"Immunity"},{"key":"913_CR91","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/leu.2011.204","volume":"26","author":"KD Boyd","year":"2012","unstructured":"Boyd, K. D. et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26, 349\u2013355 (2012).","journal-title":"Leukemia"},{"key":"913_CR92","doi-asserted-by":"publisher","first-page":"9770","DOI":"10.1073\/pnas.0703354104","volume":"104","author":"CL Haga","year":"2007","unstructured":"Haga, C. L., Ehrhardt, G. R. A., Boohaker, R. J., Davis, R. S. & Cooper, M. D. Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment. Proc. Natl Acad. Sci. 104, 9770\u20139775 (2007).","journal-title":"Proc. Natl Acad. Sci."},{"key":"913_CR93","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li, J. et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell 31, 383\u2013395 (2017).","journal-title":"Cancer Cell"},{"key":"913_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-019-0178-8","volume":"9","author":"AK Stewart","year":"2019","unstructured":"Stewart, A. K. et al. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J. 9, 1\u201312 (2019).","journal-title":"Blood Cancer J."},{"key":"913_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39395-4","volume":"14","author":"D Jiang","year":"2023","unstructured":"Jiang, D. et al. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat. Commun. 14, 3642 (2023).","journal-title":"Nat. Commun."},{"key":"913_CR96","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","volume":"9","author":"Z Yu","year":"2024","unstructured":"Yu, Z. et al. Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma. Signal. Transduct. Target. Ther. 9, 16 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"913_CR97","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1182\/blood-2023-183025","volume":"142","author":"J O\u2019Neal","year":"2023","unstructured":"O\u2019Neal, J. et al. Targeting distinct epitopes of FCRL5 using CAR-T generated with sequences derived from newly identified FCRL5 humanized antibodies resulted in potent anti-myeloma activity in vitro and in vivo. Blood 142, 1922 (2023).","journal-title":"Blood"},{"key":"913_CR98","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel, S. et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood 138, 157 (2021).","journal-title":"Blood"},{"key":"913_CR99","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2022-159381","volume":"140","author":"S Trudel","year":"2022","unstructured":"Trudel, S. et al. Pretreatment with tocilizumab prior to the CD3 bispecific cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) showed a marked reduction in cytokine release syndrome incidence and severity. Blood 140, 1363\u20131365 (2022).","journal-title":"Blood"},{"key":"913_CR100","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1182\/blood-2022-157547","volume":"140","author":"AM Lesokhin","year":"2022","unstructured":"Lesokhin, A. M. et al. Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study. Blood 140, 4415\u20134417 (2022).","journal-title":"Blood"},{"key":"913_CR101","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"140","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann, N. et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J. Clin. Oncol. 140, 1665\u20131675 (2024). Jco2302232.","journal-title":"J. Clin. Oncol."},{"key":"913_CR102","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Invest."},{"key":"913_CR103","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","volume":"132","author":"DJ Green","year":"2018","unstructured":"Green, D. J. et al. Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood 132, 1011\u20131011 (2018).","journal-title":"Blood"},{"key":"913_CR104","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/blood-2021-146518","volume":"138","author":"NS Raje","year":"2021","unstructured":"Raje, N. S. et al. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma. Blood 138, 548\u2013548 (2021).","journal-title":"Blood"},{"key":"913_CR105","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1182\/blood-2021-148390","volume":"138","author":"D Bu","year":"2021","unstructured":"Bu, D. et al. Identification and development of PHE885: a novel and highly potent fully human anti-BCMA CAR-T manufactured with a novel T-charge TM platform for the treatment of multiple myeloma. Blood 138, 2770 (2021).","journal-title":"Blood"},{"key":"913_CR106","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","volume":"41","author":"AS Sperling","year":"2023","unstructured":"Sperling, A. S. et al. Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM). J. Clin. Oncol. 41, 8004\u20138004 (2023).","journal-title":"J. Clin. Oncol."},{"key":"913_CR107","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-22-1319","volume":"14","author":"N Jain","year":"2024","unstructured":"Jain, N. et al. Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function. Cancer Discov. 14, 142\u2013157 (2024).","journal-title":"Cancer Discov."},{"key":"913_CR108","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.omtm.2022.03.018","volume":"25","author":"J Kath","year":"2022","unstructured":"Kath, J. et al. Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells. Mol. Ther. Methods Clin. Dev. 25, 311\u2013330 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"913_CR109","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","volume":"3","author":"AL Garfall","year":"2019","unstructured":"Garfall, A. L. et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 3, 2812\u20132815 (2019).","journal-title":"Blood Adv."},{"key":"913_CR110","doi-asserted-by":"publisher","first-page":"TPS8053","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053","volume":"39","author":"SZ Usmani","year":"2021","unstructured":"Usmani, S. Z. et al. KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma. J. Clin. Oncol. 39, TPS8053\u2013TPS8053 (2021).","journal-title":"J. Clin. Oncol."},{"key":"913_CR111","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-137650","volume":"136","author":"N Leblay","year":"2020","unstructured":"Leblay, N. et al. Cite-seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy. Blood 136, 11\u201312 (2020).","journal-title":"Blood"},{"key":"913_CR112","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","volume":"3","author":"KM Dhodapkar","year":"2022","unstructured":"Dhodapkar, K. M. et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 3, 490\u2013501 (2022).","journal-title":"Blood Cancer Discov."},{"key":"913_CR113","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 41, 711\u2013725 e716 (2023).","journal-title":"Cancer Cell"},{"key":"913_CR114","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","volume":"29","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K., Jain, M. D. & Smith, E. L. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transpl. Cell Ther. 29, 418\u2013428 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"913_CR115","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc. Natl Acad. Sci. USA 116, 9543\u20139551 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"913_CR116","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0, M. C. et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat. Med. 27, 616\u2013619 (2021).","journal-title":"Nat. Med."},{"key":"913_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur, M. K. et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12, 868 (2021).","journal-title":"Nat. Commun."},{"key":"913_CR118","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee, H. et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat. Med. 29, 2295\u20132306 (2023).","journal-title":"Nat. Med."},{"key":"913_CR119","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","volume":"5","author":"MS Truger","year":"2021","unstructured":"Truger, M. S. et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 5, 3794\u20133798 (2021).","journal-title":"Blood Adv."},{"key":"913_CR120","doi-asserted-by":"publisher","unstructured":"Firestone, R. S. et al. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. Blood, https:\/\/doi.org\/10.1182\/blood.2023023557 (2024).","DOI":"10.1182\/blood.2023023557"},{"key":"913_CR121","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1182\/blood-2022-167602","volume":"140","author":"H Lee","year":"2022","unstructured":"Lee, H. et al. Role of TNFRSF17 and GPRC5D structural and point mutations in resistance to targeted immunotherapies in multiple myeloma (MM). Blood 140, 252\u2013253 (2022).","journal-title":"Blood"},{"key":"913_CR122","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJMc2308544","volume":"389","author":"X Mi","year":"2023","unstructured":"Mi, X., Penson, A., Abdel-Wahab, O. & Mailankody, S. Genetic basis of relapse after GPRC5D-targeted CAR T cells. N. Engl. J. Med. 389, 1435\u20131437 (2023).","journal-title":"N. Engl. J. Med."},{"key":"913_CR123","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","volume":"4","author":"J Derrien","year":"2023","unstructured":"Derrien, J. et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat. Cancer 4, 1536\u20131543 (2023).","journal-title":"Nat. Cancer"},{"key":"913_CR124","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91\u201398 (2004).","journal-title":"J. Exp. Med."},{"key":"913_CR125","doi-asserted-by":"publisher","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","volume":"7","author":"MK Samur","year":"2023","unstructured":"Samur, M. K. et al. Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 7, 6599\u20136603 (2023).","journal-title":"Blood Adv."},{"key":"913_CR126","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen, A. D. et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141, 219\u2013230 (2023).","journal-title":"Blood"},{"key":"913_CR127","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen, D. K. et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J. Clin. Oncol. 41, 2087\u20132097 (2023).","journal-title":"J. Clin. Oncol."},{"key":"913_CR128","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","volume":"24","author":"AJ Cowan","year":"2023","unstructured":"Cowan, A. J. et al. \u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 24, 811\u2013822 (2023).","journal-title":"Lancet Oncol."},{"key":"913_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00716-3","volume":"12","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. \u03b3-Secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 12, 118 (2022).","journal-title":"Blood Cancer J."},{"issue":"Suppl. 16","key":"913_CR130","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","volume":"41","author":"HC Lee","year":"2023","unstructured":"Lee, H. C. et al. LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma [abstract]. J. Clin. Oncol. 41 (Suppl. 16), 8006 (2023).","journal-title":"J. Clin. Oncol."},{"key":"913_CR131","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","volume":"18","author":"X Miao","year":"2023","unstructured":"Miao, X. et al. Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from majesTEC-1. Target. Oncol. 18, 667\u2013684 (2023).","journal-title":"Target. Oncol."},{"key":"913_CR132","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","volume":"7","author":"S Girgis","year":"2023","unstructured":"Girgis, S. et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma. Blood Adv. 7, 644\u2013648 (2023).","journal-title":"Blood Adv."},{"issue":"Suppl. 1","key":"913_CR133","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2023-190341","volume":"142","author":"M Elmeliegy","year":"2023","unstructured":"Elmeliegy, M. et al. Soluble B-cell maturation antigen as a disease biomarker in relapsed or refractory multiple myeloma (RRMM): evaluation from elranatamab (ELRA) Magnetismm studies [abstract]. Blood 142 (Suppl. 1), 3345 (2023).","journal-title":"Blood"},{"issue":"Suppl. 16","key":"913_CR134","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","volume":"41","author":"YC Cohen","year":"2023","unstructured":"Cohen, Y. C. et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) [abstract]. J. Clin. Oncol. 41 (Suppl. 16), 8002 (2023).","journal-title":"J. Clin. Oncol."},{"key":"913_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44873-4","volume":"15","author":"F Sun","year":"2024","unstructured":"Sun, F. et al. Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth. Nat. Commun. 15, 615 (2024).","journal-title":"Nat. Commun."},{"key":"913_CR136","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","volume":"38","author":"C Li","year":"2024","unstructured":"Li, C. et al. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia 38, 149\u2013159 (2024).","journal-title":"Leukemia"},{"key":"913_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah, E. et al. Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat. Commun. 11, 2283 (2020).","journal-title":"Nat. Commun."},{"key":"913_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43416-7","volume":"14","author":"RC Larson","year":"2023","unstructured":"Larson, R. C. et al. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nat. Commun. 14, 7509 (2023).","journal-title":"Nat. Commun."},{"issue":"Suppl. 16","key":"913_CR139","doi-asserted-by":"publisher","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","volume":"41","author":"S Kumar","year":"2023","unstructured":"Kumar, S. et al. CAMMA 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent [abstract]. J. Clin. Oncol. 41 (Suppl. 16), TPS8064 (2023).","journal-title":"J. Clin. Oncol."},{"key":"913_CR140","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk, N., Usmani, S. Z. & Yong, K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 8, e446\u2013e461 (2021).","journal-title":"Lancet Haematol."},{"key":"913_CR141","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","volume":"130","author":"T Gogishvili","year":"2017","unstructured":"Gogishvili, T. et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood 130, 2838\u20132847 (2017).","journal-title":"Blood"},{"key":"913_CR142","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","volume":"28","author":"S Prommersberger","year":"2021","unstructured":"Prommersberger, S. et al. CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene Ther. 28, 560\u2013571 (2021).","journal-title":"Gene Ther."},{"key":"913_CR143","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","volume":"29","author":"C Amatya","year":"2021","unstructured":"Amatya, C. et al. Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7. Mol. Ther. 29, 702\u2013717 (2021).","journal-title":"Mol. Ther."},{"issue":"Suppl. 1","key":"913_CR144","first-page":"502","volume":"130","author":"R Mathur","year":"2017","unstructured":"Mathur, R. et al. Universal SLAMF7-specific CAR T-cells as treatment for multiple myeloma [abstract]. Blood 130 (Suppl. 1), 502 (2017).","journal-title":"Blood"},{"key":"913_CR145","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano, Y. et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263, 160\u2013172 (2015).","journal-title":"Immunol. Rev."},{"key":"913_CR146","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.3390\/ijms22094462","volume":"22","author":"N Giannakoulas","year":"2021","unstructured":"Giannakoulas, N., Ntanasis-Stathopoulos, I. & Terpos, E. The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. Int. J. Mol. Sci. 22, 4462 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"913_CR147","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J. Hematol. Oncol. 9, 116 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"913_CR148","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","volume":"26","author":"AD Cohen","year":"2020","unstructured":"Cohen, A. D. et al. How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clin. Cancer Res. 26, 1541\u20131554 (2020).","journal-title":"Clin. Cancer Res."},{"key":"913_CR149","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","volume":"117","author":"BM Russell","year":"2023","unstructured":"Russell, B. M. & Avigan, D. E. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy. Int. J. Hematol. 117, 652\u2013659 (2023).","journal-title":"Int. J. Hematol."},{"key":"913_CR150","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2016.84","volume":"30","author":"H Suen","year":"2016","unstructured":"Suen, H. et al. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 30, 1716\u20131724 (2016).","journal-title":"Leukemia"},{"key":"913_CR151","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1242\/dmm.008961","volume":"5","author":"J Hu","year":"2012","unstructured":"Hu, J., Van Valckenborgh, E., Menu, E., De Bruyne, E. & Vanderkerken, K. Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis. Model. Mech. 5, 763\u2013771 (2012).","journal-title":"Dis. Model. Mech."},{"key":"913_CR152","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping, N. E. et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat. Immunol. 22, 205\u2013215 (2021).","journal-title":"Nat. Immunol."},{"key":"913_CR153","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/leu.2010.193","volume":"24","author":"S Colla","year":"2010","unstructured":"Colla, S. et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1\u03b1 overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells. Leukemia 24, 1967\u20131970 (2010).","journal-title":"Leukemia"},{"key":"913_CR154","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij, C. P. M. et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 5, 2196\u20132215 (2021).","journal-title":"Blood Adv."},{"key":"913_CR155","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003975","volume":"10","author":"J Sun","year":"2022","unstructured":"Sun, J. et al. Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. J. Immunother. Cancer 10, e003975 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"913_CR156","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","volume":"25","author":"ZX Yan","year":"2019","unstructured":"Yan, Z. X. et al. Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin\u2019s lymphoma. Clin. Cancer Res. 25, 6995\u20137003 (2019).","journal-title":"Clin. Cancer Res."},{"key":"913_CR157","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907\u2013912 (2005).","journal-title":"J. Exp. Med."},{"key":"913_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00929-0","volume":"13","author":"S Sidana","year":"2023","unstructured":"Sidana, S. et al. Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer J. 13, 158 (2023).","journal-title":"Blood Cancer J."},{"key":"913_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08711-2","volume":"10","author":"M Luu","year":"2019","unstructured":"Luu, M. et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. Nat. Commun. 10, 760 (2019).","journal-title":"Nat. Commun."},{"key":"913_CR160","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","volume":"29","author":"CK Stein-Thoeringer","year":"2023","unstructured":"Stein-Thoeringer, C. K. et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat. Med. 29, 906\u2013916 (2023).","journal-title":"Nat. Med."},{"key":"913_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32960-3","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat. Commun. 13, 5313 (2022).","journal-title":"Nat. Commun."},{"issue":"Suppl.","key":"913_CR162","doi-asserted-by":"publisher","first-page":"e90062ca","DOI":"10.1097\/01.HS9.0000967680.90062.ca","volume":"7","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis, N. J. et al. Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results [abstract S192]. HemaSphere 7 (Suppl.), e90062ca (2023).","journal-title":"HemaSphere"},{"key":"913_CR163","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp, N. et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 140, 1104\u20131118 (2022).","journal-title":"Blood"},{"key":"913_CR164","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00913-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00913-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00913-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T13:08:11Z","timestamp":1721740091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00913-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":164,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00913-y","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"5 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.N. reports honoraria from Bristol Myers Squibb (BMS), Janssen, Pfizer and Sanofi, and is a consultant\/advisory board member for BMS and Janssen. N.J.B. reports honoraria from Amgen, BMS, Janssen, Pfizer and Sanofi, and is a consultant\/advisory board member for BMS, Janssen and Pfizer. K.C.A. is a consultant\/advisory board member for Amgen, Astrazeneca, Janssen and Pfizer, and is a board member of 4 Therapeutics, Dynamic Cell Therapies, Next RNA, Starton Therapeutics and Window Therapeutics. N.L., H.L. and A.G. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}